Occurrence of MYD88L265P and CD79B mutations in diffuse large b cell lymphoma with bone marrow infiltration: A case report

Table 1 Summary of previously published series of cases

Ref.	No. of case	A/G	BM	Extramedullary site	Histological type	Staging	Therapy	Interval (mo)1	Ending	Survival (mo)
Uchino et al[18]	1	55/M	+	Spleen	Nospecified	IV B	R-CHOP	408	CR	> 17
Owen et al[19]	2	80/M	+	Mesenteric mass	ABC	IV	R-CVP	36	Dead	No specified
Owen et al[19]	3	63/M	+	Lymphadenopath	GCB	IV	R-CHOP	84	PR	No specified
Shiseki et al[20]	4	63/M	+	Lymph node	No specified	IV	THP-COP	36	CR	> 60
Kikukawa et al[21]	5	60/F	+	Brain	ABC	IV	R-MPV, WBRT+Ara-C	72	PR	> 6
Okolo et al[22]	6	69/M	+	Retroperitoneal mass	No specified	IV	R-CHOP, DRC	Unknown	CR	No specified
Kobayashi et al[23]	7	75/M	+	Liver and ileum	GCB	IV	R-CHOP	120	PR	No specified
Elimimian et al[24]	8	60/M	+	Inguinal lymph node	ABC	IV A	O+CHOP, DHAP	168	Dead	4

¹Interval from the diagnosis of lymphoplasmic lymphoma/Waldenstrom macroglobulinemia to the diagnosis of diffuse large B cell lymphoma.

BM: Bone marrow; CR: Complete response; PR: Partial response; R-CVP: Rituximab, cyclophosphamide, vincristine, prednisone; R-CHOP: Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone; THP: Epirubicin; R-MPV: Methotrexate, vincristine, procarbazine; WBRT: Whole-brain radiation; Ara-C: Cytarabine; DRC: Dexamethasone, rituximab, cyclophosphamide; O: Obinutuzumab; DHAP: Cisplatin, cytarabine, dexamethasone.